SCHEMBL14413272

SCHEMBL14413272

O=C(O)c1c(O)ccc(/N=N/c2ccc(/N=N/c3ccc4c(S(=O)(=O)O)cccc4c3O)c3ccccc23)c1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 5/20 0.74
▸ CTRB1 P17538 1/20 0.58
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ NSD2 O96028 2/20 0.53
▸ POLB P06746 1/20 0.53
▸ IDE P14735 1/20 0.53
▸ DUSP3 P51452 1/20 0.53
▸ CCR6 P51684 1/20 0.53
▸ BLM P54132 1/20 0.53
▸ ATIC P31939 2/20 0.49
▸ MPL P40238 4/20 0.47
▸ CTRC Q99895 1/20 0.47
▸ THRB P10828 2/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ HIF1A Q16665 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ STAT6 P42226 1/20 0.43
▸ ENPP2 Q13822 1/20 0.41
▸ MMP14 P50281 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12960419 0.80 CYP1A2 (0.82) CYP1A2CTRB1MEN1KMT2ANSD2
SCHEMBL14580408 0.79 CYP1A2 (0.60) CYP1A2CTRB1MEN1KMT2ANSD2
SCHEMBL6654290 0.78 CTRB1 (0.82) CYP1A2CTRB1MEN1KMT2ANSD2
SCHEMBL7764792 0.77 MPL (0.70) CYP1A2CTRB1MEN1KMT2ANSD2
SCHEMBL28551711 0.76 CYP1A2 (0.70) CYP1A2CTRB1MEN1KMT2ANSD2
SCHEMBL25926116 0.76 CYP1A2 (0.70) CYP1A2CTRB1MEN1KMT2ANSD2
SCHEMBL15115349 0.76 CYP1A2 (0.70) CYP1A2CTRB1MEN1KMT2ANSD2
E122 SCHEMBL110093 0.75 CYP1A2 (0.78) CYP1A2CTRB1MEN1KMT2ANSD2
E122 SCHEMBL345295 0.75 CYP1A2 (0.78) CYP1A2CTRB1MEN1KMT2ANSD2
SCHEMBL29378273 0.75 CYP1A2 (0.68) CYP1A2CTRB1MEN1KMT2ANSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 — — US disclosed
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same AMBION, INC (US) 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same RNASE1, RNASEH1, RNASEL CYP1A2 4375/4885CTRB1 141/4885MEN1 2073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback